Orion Group

Activities: Manufacturing Ingredients Analysis Pharmaceutical Dietary supplements Active Nutrition Food

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Finance

Orion to open new biologics R&D centre in Cambridge, UK, in 2025

Biologics are the fastest growing segment in pharma, representing huge opportunities for new innovative treatments
Sustainability

Orion’s near-term climate targets approved by the Science Based Targets initiative

Orion Corporation is proud to announce that the Science Based Targets initiative (SBTi) has validated its near-term science-based targets
Research & Development

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

Orion Corporation and Glykos Finland Oy have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs)
Research & Development

Orion and MSD announce two Phase III trials to evaluate ODM-208/MK5684 in patients with metastatic castration-resistant prostate cancer

OMAHA1 and OMAHA2a are the first Phase III trials to be initiated for ODM-208/MK5684
Distribution

Orion and Amneal enter distribution partnership

The initial portfolio will include a mix of generic products commercially available in the US today
Research & Development

Orion and MSD announce global collaboration to develop and commercialise ODM-208

Agreement strengthens and complements MSD’s oncology pipeline
Distribution

Orion to commercialise Jemincare pain treatment

Under the agreement, Orion will receive global development and commercialisation rights outside of mainland China, Hong Kong, Macau and Taiwan
Subscribe now